{
    "clinical_study": {
        "@rank": "164798", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Arm C", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Arm D", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will examine the next-day residual effects of a nighttime dose of gabapentin 250\n      mg, diphenhydramine citrate 76 mg and triazolam 0.5 mg compared to placebo and each other on\n      simulated driving performance in normal volunteer subjects.  It will also examine other\n      measures of next-day performance and next-day sleepiness."
        }, 
        "brief_title": "Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males and females of non-childbearing potential, 25-55 years of age\n\n          -  Valid driver's license\n\n        Exclusion Criteria:\n\n          -  Psychiatric disorder\n\n          -  Recent history of clinically significant neurological disorder, such as seizures,\n             stroke, multiple sclerosis, or head trauma\n\n          -  Recent histroy or current treatment for sleep disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "59", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01888497", 
            "org_study_id": "A9451178"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A", 
                "description": "250 mg, oral, prior to bedtime on the night before performance testing", 
                "intervention_name": "Gabapentin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B", 
                "description": "76 mg, oral, prior to bedtime on the night before performance testing", 
                "intervention_name": "Diphenhydramine citrate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm C", 
                "description": "0.5 mg, oral, prior to bedtime on the night before performance testing", 
                "intervention_name": "Triazolam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm D", 
                "description": "Oral, prior to bedtime on the night before performance testing", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Diphenhydramine", 
                "Promethazine", 
                "Triazolam", 
                "Gabapentin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Sleeplessness", 
        "lastchanged_date": "April 2, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9451178&StudyName=Next-Day%20Residual%20Effects%20of%20Gabapentin%2C%20Diphenhydramine%20and%20Triazolam%20on%20Simulated%20Driving%20Performance%20in%20Normal%20Volunteers"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "South Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }, 
                    "name": "Baptist Sleep Centers, LLP"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "South Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }, 
                    "name": "Miami Research Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30342"
                    }, 
                    "name": "NeuroTrials Research Sleep Lab"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30342"
                    }, 
                    "name": "NeuroTrials Research, Inc."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 3 Randomized, Double-blind, Cross-over, Placebo-controlled, Multi-center, Single-dose, Clinical Trial to Assess the Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Standard Deviation of Lateral Position", 
            "safety_issue": "Yes", 
            "time_frame": "7.25 hours post dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01888497"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Speed Deviation", 
                "safety_issue": "Yes", 
                "time_frame": "7.25 hours post dosing"
            }, 
            {
                "measure": "Lane Exceedances", 
                "safety_issue": "Yes", 
                "time_frame": "7.25 hours post dosing"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}